Best Biotech & Generics
Stocks in 2026

The Biotech & Generics universe combines two complementary forces in modern medicine. Biotechnology companies focus on developing innovative treatments, such as cell and gene therapies, monoclonal antibodies and RNA-based drugs. Often through high-risk R&D and in partnership with major pharmaceutical firms, as demonstrated during the COVID-19 pandemic. In parallel, generic and biosimilar manufacturers play a critical role in expanding access to medicines by offering lower-cost alternatives to branded drugs. This segment is well-positioned to benefit from the current wave of blockbuster patent expirations (loss of exclusive rights) and increasing global pressure to reduce healthcare costs.